SCHEMBL23749867

SCHEMBL23749867

N=c1scc(C2CC2)n1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GSK3B P49841 3/20 0.39
GSK3A P49840 2/20 0.39
HTT P42858 2/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38
SLC2A1 P11166 1/20 0.37
ALKBH5 Q6P6C2 1/20 0.36
ACHE P22303 2/20 0.36
BCHE P06276 1/20 0.36
CYP19A1 P11511 2/20 0.36
HSD17B10 Q99714 2/20 0.36
G6PD P11413 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23727102 0.75 HSD17B10 (0.39) LMNASMN1; SMN2ALDH1A1MAPTGSK3B
SCHEMBL23727101 0.75 HSD17B10 (0.39) LMNASMN1; SMN2ALDH1A1MAPTGSK3B
SCHEMBL23749756 0.73 SMN1; SMN2 (0.47) LMNASMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL25002134 0.71 POLB (0.46) LMNASMN1; SMN2MAPTKDM4EKMT2A
SCHEMBL23750073 0.71 SMN1; SMN2 (0.44) LMNASMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL23749767 0.71 LMNA (0.44) LMNASMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL23749771 0.70 LMNA (0.47) LMNASMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL23749889 0.69 ALDH1A1 (0.44) LMNASMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL22001636 0.66 FUCA1 (0.55) ALDH1A1ACHEBCHESIGMAR1CCR3
SCHEMBL9161101 0.64 L3MBTL1 (0.65) LMNASMN1; SMN2KDM4EGSK3BGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 US disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 EP disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
CN-115515579-A Pyrrolo [2,3-b ] pyridine-3-carboxamide compositions and methods for ameliorating hearing loss 洛克菲勒大学 2022-12-23 CN disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 EP disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 LMNA 501/4885SMN1; SMN2 2879/4885ALDH1A1 2546/4885
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 LMNA 1731/4885SMN1; SMN2 2796/4885ALDH1A1 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.